Results 191 to 200 of about 75,992 (272)

Indianapolis Consensus Recommendations for Promoting Diversity and Equity in Cancer Clinical Trials: “The Indianapolis Black Paper”

Diversity &Inclusion Research, Volume 3, Issue 3, July 2026.
ABSTRACT Cancer mortality is inequitably distributed across the U.S. and globally, with historically marginalized groups, particularly racial and ethnic minorities, being disproportionately affected. Disproportionate representation in clinical cancer research is a consequence of inequitable access as well as a central factor contributing to outcome ...
Maya N. Birhiray, Andrew Hantel, Joseph R. Mikhael, Kenneth C. Anderson, Ayalew Tefferi, Samuel L. Ranger, Ruemu E. Birhiray, for the Indianapolis Black Paper Group, Sybil Green, Saad Usmani, Mary Owen, Eucharia Borden, Jacqueline Barrientos, Muzzafar Qazilbash, Richard Stone, Rafat Abonour, Coleman Obasaju, Nada Hamad, Irby Hunter, Adrian Barfield, Sandra Garofalo, John Leonard, Martin Tallman   +22 more
wiley   +1 more source

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis. [PDF]

Acta Oncol
Caeyman A, Mammone G, Kinget L, Baldewijns M, De Wever L, Albersen M, Debruyne PR, Demeulenaere O, McTaggart ES, Saraswat S, Berghen C, De Meerleer G, Naulaerts S, Garg AD, Beuselinck B.   +14 more
europepmc   +1 more source

Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers

Head &Neck, Volume 48, Issue 7, Page 1876-1884, July 2026.
ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh, Labani Kole, Richard Sullivan, Shwetabh Sinha, Rathan Shetty, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Kumar Prabhash, Pankaj Chaturvedi   +9 more
wiley   +1 more source

Nivolumab-associated hypopituitarism in a 61-year-old woman with metastatic triple-negative breast. [PDF]

Oxf Med Case Reports
Lomidze K, Gordeladze M, Kikodze N, Charkviani N, Chikovani T.   +4 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study. [PDF]

ESMO Open
Cigliola A, Maiorano BA, Rossari F, Tateo V, Mercinelli C, Dizman N, Colecchia M, De Cobelli F, Larcher A, Rosiello G, Briganti A, Montorsi F, Capitanio U, Spiess PE, Agarwal N, Pal SK, Necchi A.   +16 more
europepmc   +1 more source

Clinical efficacy of anti-PD-1 immunotherapy with localized non-ablative irradiation against metastatic lymph node in patients with metastatic gastric cancer. [PDF]

Clin Transl Radiat Oncol
Mimura K, Suzuki Y, Nakajima S, Ogata T, Fehlings M, Saito K, Yoshimoto Y, Yoshida D, Machida N, Yamada T, Katoh H, Hanayama H, Nardin A, Saze Z, Takahashi F, Oshima T, Kono K.   +16 more
europepmc   +1 more source

Temperature Dependent Motions of N‐Terminal Loop in PD‐1 Determine the Affinity Towards Nivolumab

Journal of Molecular Recognition, Volume 39, Issue 4, July 2026.
ABSTRACT Programmed Cell Death—1 receptors on the surface of monocytes and T and B cells modulate various immune responses and are key immunotherapy targets. Immunotherapeutic monoclonal antibodies, including Nivolumab, block the activity of this receptor and are a mainstay of cancer therapy.
Mohammad Karbalaeimahdi, Dircia C. C. Marcelina, Razvan C. Stan   +2 more
wiley   +1 more source

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma. [PDF]

Front Endocrinol (Lausanne)
Hasan M, Samlowski W, Nakhle S.
europepmc   +1 more source

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

MedComm, Volume 7, Issue 7, July 2026.
This phase II trial suggests the potential of perioperative camrelizumab plus neoadjuvant chemotherapy in patients with resectable stage IIB‐IIIB lung squamous cell carcinoma. The major pathological response rate (primary endpoint) was 60.0%, and the pathological complete response (pCR) rate was 44.4%.
Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang   +17 more
wiley   +1 more source